安进 JPM 2025 Presentation _ Final.pdf

1、ROBERT A.BRADWAY,CHAIRMAN AND CHIEF EXECUTIVE OFFICERJanuary 13,202543rdANNUAL J.P.MORGAN HEALTHCARE CONFERENCE2Provided January 13,2025,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen disclaims any duty to update.

2、SAFE HARBOR STATEMENTThis presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen.All statements,other than statements of historical fact,are statements that could bedeemed forward-looking statements,including any statements on the outcome,ben

3、efits and synergies of collaborations,or potential collaborations,with any other company(including BeiGene,Ltd.orKyowa Kirin Co.,Ltd.),the performance of Otezla(apremilast)(including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion),our acquisitions of Teneobio,Inc.,ChemoCent

4、ryx,Inc.,orHorizon Therapeutics plc(including the prospective performance and outlook of Horizons business,performance and opportunities,any potential strategic benefits,synergies or opportunities expected as aresult of such acquisition,and any projected impacts from the Horizon acquisition on our a

5、cquisition-related expenses going forward),as well as estimates of revenues,operating margins,capital expenditures,cash,other financial metrics,expected legal,arbitration,political,regulatory or clinical results or practices,customer and prescriber patterns or practices,reimbursement activities and

6、outcomes,effects ofpandemics or other widespread health problems on our business,outcomes,progress,and other such estimates and results.Forward-looking statements involve significant risks and uncertainties,includingthose discussed below and more fully described in the Securities and Exchange Commis